Multivariable Model for Factors Associated With Systolic Blood Pressure Elevation at 72 and 96 Weeks Post Antiretroviral Therapy Initiation
| Factor . | Estimated Difference in SBP (95% CI) 72 weeks . | P value . | Estimated Difference in SBP (95% CI) 96 weeks . | P value . |
|---|---|---|---|---|
| INSTI-based ART | 5.4 (0.4–13.1) | .095 | 7.0 (0.3–13.7) | .039 |
| Baseline HIV-1 RNA >100 000 copies/mL | 3.7 (-5.8–6.9) | .260 | 5.0 (-1.5–11.4) | .130 |
| Female | 11.8 (4.2–19.7) | .002 | 8.5 (1.1–16.0) | .026 |
| IDU | 18.1 (-0.7–16.7) | <.001 | 11.4 (2.0–20.9) | .018 |
| Baseline BMI | 3.0a | .112 | 3.4a | .047 |
| Baseline CD4+ T cell count | 1.0a | .677 | 1.0a | .406 |
| Age | 2.4a | .162 | 1.4a | .489 |
| Factor . | Estimated Difference in SBP (95% CI) 72 weeks . | P value . | Estimated Difference in SBP (95% CI) 96 weeks . | P value . |
|---|---|---|---|---|
| INSTI-based ART | 5.4 (0.4–13.1) | .095 | 7.0 (0.3–13.7) | .039 |
| Baseline HIV-1 RNA >100 000 copies/mL | 3.7 (-5.8–6.9) | .260 | 5.0 (-1.5–11.4) | .130 |
| Female | 11.8 (4.2–19.7) | .002 | 8.5 (1.1–16.0) | .026 |
| IDU | 18.1 (-0.7–16.7) | <.001 | 11.4 (2.0–20.9) | .018 |
| Baseline BMI | 3.0a | .112 | 3.4a | .047 |
| Baseline CD4+ T cell count | 1.0a | .677 | 1.0a | .406 |
| Age | 2.4a | .162 | 1.4a | .489 |
Abbreviaitons: ART, antiretroviral therapy; BMI, body mass index; CI, confidence interval; IDU, injection drug use; INSTI, Integrase Strand Transfer Inhibitors; SBP, systolic blood pressure.
aNonlinear, adjusted by generalized additive mixed model.
Multivariable Model for Factors Associated With Systolic Blood Pressure Elevation at 72 and 96 Weeks Post Antiretroviral Therapy Initiation
| Factor . | Estimated Difference in SBP (95% CI) 72 weeks . | P value . | Estimated Difference in SBP (95% CI) 96 weeks . | P value . |
|---|---|---|---|---|
| INSTI-based ART | 5.4 (0.4–13.1) | .095 | 7.0 (0.3–13.7) | .039 |
| Baseline HIV-1 RNA >100 000 copies/mL | 3.7 (-5.8–6.9) | .260 | 5.0 (-1.5–11.4) | .130 |
| Female | 11.8 (4.2–19.7) | .002 | 8.5 (1.1–16.0) | .026 |
| IDU | 18.1 (-0.7–16.7) | <.001 | 11.4 (2.0–20.9) | .018 |
| Baseline BMI | 3.0a | .112 | 3.4a | .047 |
| Baseline CD4+ T cell count | 1.0a | .677 | 1.0a | .406 |
| Age | 2.4a | .162 | 1.4a | .489 |
| Factor . | Estimated Difference in SBP (95% CI) 72 weeks . | P value . | Estimated Difference in SBP (95% CI) 96 weeks . | P value . |
|---|---|---|---|---|
| INSTI-based ART | 5.4 (0.4–13.1) | .095 | 7.0 (0.3–13.7) | .039 |
| Baseline HIV-1 RNA >100 000 copies/mL | 3.7 (-5.8–6.9) | .260 | 5.0 (-1.5–11.4) | .130 |
| Female | 11.8 (4.2–19.7) | .002 | 8.5 (1.1–16.0) | .026 |
| IDU | 18.1 (-0.7–16.7) | <.001 | 11.4 (2.0–20.9) | .018 |
| Baseline BMI | 3.0a | .112 | 3.4a | .047 |
| Baseline CD4+ T cell count | 1.0a | .677 | 1.0a | .406 |
| Age | 2.4a | .162 | 1.4a | .489 |
Abbreviaitons: ART, antiretroviral therapy; BMI, body mass index; CI, confidence interval; IDU, injection drug use; INSTI, Integrase Strand Transfer Inhibitors; SBP, systolic blood pressure.
aNonlinear, adjusted by generalized additive mixed model.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
